Shares of Kymera Therapeutics, Inc. (KYMR) are climbing about 21 percent on Thursday morning after the company has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621 for the treatment of moderate to severe atopic dermatitis.
The company's shares are currently trading at $121.31 on the Nasdaq, up 20.79 percent. The stock opened at $108.88 and has climbed as high as $130.05 so far in today's session. Over the past year, it has traded in a range of $36.65 to $130.05.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.